Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to Strong-Buy Rating
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Read Our […]
4 Apr 02:24 · The Cerbat Gem